Forest/Richter's radiprodil fails Phase II study for diabetic neuropathic pain
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Gedeon Richter have announced that radiprodil (RGH-896) has shown no statistically significant or clinically meaningful improvements in a Phase II trial for the treatment of peripheral neuropathic pain associated with type 1 or type 2 diabetes.